Matthew D. Tallant

发表

Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents.

C. Moore, A. Mathis, J. Botyánszki, 2014, Journal of medicinal chemistry.

Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.

R. Hamatake, Suoming Zhang, S. Baker, 2012, Journal of medicinal chemistry.

Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.

Z. Ni, Suoming Zhang, S. Baker, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.

Z. Ni, Suoming Zhang, S. Baker, 2010, Bioorganic & medicinal chemistry letters.

Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.

R. Hamatake, Suoming Zhang, S. Baker, 2012, Bioorganic & medicinal chemistry letters.

Exo-selective Diels-Alder reactions of vinylazepines. Origin of divergent stereoselectivity in Diels-Alder reactions of vinylazepines, vinylpiperideines, and vinylcycloalkenes.

G. Sulikowski, J. Reibenspies, Matthew D. Tallant, 2003, The Journal of organic chemistry.

Metal Ion Complexation and Extraction Behavior of Some Acyclic Analogs oftert-Butyl-calix[4]arene Hydroxamate Extractants

T. Lambert, A. Gopalan, Matthew D. Tallant, 2000 .

Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties.

Z. Ni, Suoming Zhang, S. Baker, 2011, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1.

W. Kazmierski, G. A. Freeman, R. Ferris, 2011, Bioorganic & medicinal chemistry letters.

Discovery of a novel series of cyclic urea as potent CCR5 antagonists.

W. Kazmierski, R. Ferris, J. Jun, 2011, Bioorganic & medicinal chemistry letters.

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.

R. Hamatake, W. Kazmierski, R. Crosby, 2014, Journal of medicinal chemistry.